Cited by 73Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisIL-33, ST2, and ILC PathwaysAsthma and respiratory diseases

Evidence for a Functional Thymic Stromal Lymphopoietin Signaling Axis in Fibrotic Lung Disease

Open access
Datta, Arnab, Alexander, Robert, Sulikowski, Michal G, Nicholson, Andrew G, Maher, Toby M, Scotton, Chris J, Chambers, Rachel C·2013·The Journal of Immunology

Abstract

Thymic stromal lymphopoietin (TSLP) recently has emerged as a key cytokine in the development of type 2 immune responses. Although traditionally associated with allergic inflammation, type 2 responses are also recognized to contribute to the pathogenesis of tissue fibrosis. However, the role of TSLP in the development of non–allergen-driven diseases, characterized by profibrotic type 2 immune phenotypes and excessive fibroblast activation, remains underexplored. Fibroblasts represent the key effector cells responsible for extracellular matrix production but additionally play important immunoregulatory roles, including choreographing immune cell recruitment through chemokine regulation. The aim of this study was to examine whether TSLP may be involved in the pathogenesis of a proto-typical fibrotic disease, idiopathic pulmonary fibrosis (IPF). We combined the immunohistochemical analysis of human IPF biopsy material with signaling studies by using cultured primary human lung fibroblasts and report for the first time, to our knowledge, that TSLP and its receptor (TSLPR) are highly upregulated in IPF. We further show that lung fibroblasts represent both a novel cellular source and target of TSLP and that TSLP induces fibroblast CCL2 release (via STAT3) and subsequent monocyte chemotaxis. These studies extend our understanding of TSLP as a master regulator of type 2 immune responses beyond that of allergic inflammatory conditions and suggest a novel role for TSLP in the context of chronic fibrotic lung disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1300588

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 89 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Datta, A., Alexander, R., Sulikowski, M. G., Nicholson, A. G., Maher, T. M., Scotton, C. J., & Chambers, R. C.
Affiliations
  • University College London (GB)
  • Royal Brompton Hospital (GB)
Corresponding author
  • Datta, Arnab
  • Alexander, Robert
Venue
The Journal of Immunology
Published
2013-11-01
Volume
191
Issue
9
Pages
4867-4879
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2108352507
Cited by
73
References
89
Citations by year
2026: 5 · 2025: 5 · 2024: 7 · 2023: 7 · 2022: 6 · 2021: 3 · 2020: 7 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 6 · 2015: 4 · 2014: 4
FWCI
3.80
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
  • GlaxoSmithKline
  • Wellcome Trust (084382, 084382/Z/07/Z)
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Keywords
thymic stromal lymphopoietin, idiopathic pulmonary fibrosis, Th2 immune response, lung fibroblasts, TSLP receptor, MCP-1, STAT3, monocyte chemotaxis, fibrosis, chemokine regulation, extracellular matrix
MeSH terms
Thymic Stromal Lymphopoietin, Cells, Cultured, Chemotaxis, Fibroblasts, Fibrosis, Humans, Inflammation, Lung, Signal Transduction, Interleukin-7, Cytokines, Receptors, Cytokine, Chemokine CCL2, RNA Interference, RNA, Small Interfering, STAT3 Transcription Factor, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review